How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide
- Author
- Tiffany Richards, Tiffany Richards PhD ANP-BC AOCNP
- Published
- Fri 16 Jul 2021
- Episode Link
- https://oncologypodcast.simplecast.com/episodes/how-to-integrate-novel-treatment-classes-for-r-r-myeloma-into-clinical-practice-information-on-selinexor-venetoclax-and-melphalan-flufenamide-afP2oiNW
In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, venetoclax, and melphalan flufenamide—into clinical practice for patients with multiple myeloma after multiple relapses. Check back to hear part 2 of this series with a discussion on BCMA-targeted therapy by Donna Catamero, ANP-BC, OCN, CCRC, Associate Director of Myeloma Translational Research at the Mount Sinai Health System.
Presenter:
Tiffany Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas
CE/AAPA credit available by visiting the online program: https://bit.ly/3ee9Ivs
Link to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs
